Celldex Therapeutics has unveiled promising early-stage data for its investigational antibody CDX-622, designed to modulate immune responses in chronic inflammatory conditions. The phase 1 trial met its primary safety endpoints and showed preliminary signs of biological activity, according to a company statement. The news sent Celldex shares up by more than 12 per cent in pre-market trading on the Nasdaq, reflecting renewed optimism around the company's pipeline.
CDX-622 is a bispecific antibody that simultaneously targets two key inflammatory mediators, potentially offering a more targeted approach than existing therapies. Analysts at Jefferies noted that the data, while early, 'de-risks' the programme and could position Celldex as a contender in the autoimmune disease space. The company plans to present full results at an upcoming medical conference.
For UK investors, the development has a direct bearing on the London-listed biotech sector. Shares of companies such as Synairgen and Arecor Therapeutics saw modest gains in sympathy trading, as the wider market digested the positive readout. The FTSE All-Share Pharmaceuticals & Biotechnology index edged up 0.3 per cent, outperforming the flat FTSE 100.
Background: Celldex, headquartered in Massachusetts, has historically focused on oncology but is increasingly pivoting toward immunology. The global market for autoimmune disease treatments is projected to exceed £100bn by 2030, making successful candidates highly valuable. However, phase 1 data, while encouraging, does not guarantee success in later-stage trials, which typically take several years.
Implications for UK pension holders: Many UK pension funds hold diversified exposure to global healthcare through index trackers or actively managed funds. A successful CDX-622 could boost the broader biotech segment, but investors should be aware that early-stage biotech remains high-risk. Analysts caution against drawing firm conclusions from single-trial data.
Source: Celldex Therapeutics press release